Deals

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease
Abogen BiosciencesmRNA

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

Abogen Biosciences Co., Ltd. ("Abogen"), a clinical‑stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Novartis AG (NYSE: NVS) to advance…

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases
Novo NordiskNYSE: NVO

Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Diseases

AbbVie Exercises Option for Capsida's Neurodegenerative Disease Program
AbbVieCapsida Biotherapeutics

AbbVie Exercises Option for Capsida’s Neurodegenerative Disease Program

PostEra Expands Partnership with Pfizer to Launch New ADC Collaboration
AINYSE: PFE

PostEra Expands Partnership with Pfizer to Launch New ADC Collaboration

Merck KGaA Adopts Quris AI's Bio-AI Platform for Drug Development Pipeline
AIETR: MRK

Merck KGaA Adopts Quris AI’s Bio-AI Platform for Drug Development Pipeline

Show More